Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the U.S. Health Resources and Services Administration (HRSA) website.
Lilly said the price restatements resulted in both upward and downward adjustments to its 340B prices. Its notice includes a table showing nine NDCs whose 340B prices rose.
Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the U.S. Health Resources and Services Administration (HRSA) website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
